Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren's syndrome that show potential to predict and monitor clinical response.
Safae HamkourEefje Hm van der HeijdenAna P LopesSofie L M BloklandCornelis P J BekkerCornelia G Van Helden-MeeuwsenMarjan A VersnelAike A KruizeTimothy Rdj RadstakeHelen L LeavisMaarten R HillenJoel Ag van RoonPublished in: RMD open (2023)
LEF/HCQ combination therapy targets type-I IFN-associated proteins that are associated with strongly decreased B cell hyperactivity and disease activity. IFN-associated Galectin-9 is a promising biomarker for treatment prediction and monitoring in pSS patients treated with LEF/HCQ.